Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 30 Nov 2012 |
| 823,000 Orion A-shares converted into B-shares | 19 Nov 2012 |
| Orion Group Interim Report January-September 2012 | 23 Oct 2012 |
| Composition of the Nomination Committee of Orion Corporation | 23 Oct 2012 |
| Orion upgrades full-year outlook for 2012 | 9 Oct 2012 |